In drug discovery, a failed sample run is not just a setback – it can mean months of lost work and significant cost. At Analytica 2026, three Eppendorf experts explain how the right tools, workflows and mindset are changing that.
Functional genomics is central to modern drug discovery, yet high attrition rates persist. In this article, Dr Salman Tamaddon-Jahromi, a postdoctoral research associate at the University of Cambridge, discusses how end-to-end CRISPR screening strategies, iPSC-derived neuronal models and layered quality control can convert functional genomics signals into actionable therapeutic hypotheses.
Two approaches to AI in preclinical drug discovery are diverging, from multi-thousand GPU systems to models with only a handful of parameters, with early results raising questions about which will deliver.
Drug Target Review has launched an updated website to improve access to content across early-stage drug discovery, alongside a new membership model that provides full access to premium analysis, reports and expert commentary.
Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.